According to a recent FDA safety communication, Rheumatoid arthritis patients taking the 10 mg twice-daily dose of Xeljanz or Xeljanz XR may be at an increased risk for blood clots in the lungs (pulmonary embolism) and death.
The FDA issued this warning following the release of data from a clinical study of the drug showing an increased risk. The FDA warns patients to be aware of this risk and to watch for signs of pulmonary embolism (PE), which may include:
- shortness of breath,
- difficulty breathing,
- chest pain,
- coughing up blood,
- excessive sweating, and
- clammy or bluish-colored skin.
On February 25, 2019, the FDA released a safety communication notifying the public of an increased risk of blood clots in the lungs and death in RA patients taking the 10 mg twice-daily dose of Xeljanz or Xeljanz XR. At the time of this writing, the FDA had not approved the 10mg twice-daily dose for RA-only for ulcerative colitis.
The FDA based this action on the results of the ongoing clinical trial they required Pfizer to conduct when they originally approved the drug in 2012.
Though the trial is not yet complete, the most recent analysis of the data showed an increased occurrence of blood clots in the lungs and death in patients treated with 10 mg twice daily compared to patients treated with 5mg twice daily, or with the alternative medication.
Because of these results, the FDA advised patients to talk to their doctors about their dosages and to watch for signs of pulmonary embolism (PE). They also encouraged healthcare professionals to follow the prescribing information for the specific condition they are treating and to monitor patients for signs of blood clots and pulmonary embolism.
Patients who take Xeljanz may be at increased risk for:
- Blood clots
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
If you or a loved one has taken Xeljanz and suffered any of the above injuries, call PW immediately for a free consultation at 954-462-6700.
$12.2m verdict against manufacturer for defective automobile
$6.5m verdict with a tobacco company
$6m verdict against a tobacco company
$5.5m verdict against a tobacco company
$2.1m verdict against a tobacco company
$1.8m verdict against a tobacco company
$1.4m verdict in breach of contract case
$1.35m verdict with a tobacco company
$1.24m settlement with a tobacco company
$1.1m settlement with a tobacco company
$1 million medical malpractice settlement
$850k defective automobile settlement
$837k trucking accident settlement
$825k wrongful death settlement
$550k settlement with a tobacco company
$500k auto negligence settlement
$450k auto negligence settlement
$400k auto negligence settlement
$350k settlement against manufacturer of defective product
Ready to win?
It all starts with your free initial consultation.
Contact us for your free initial consultation.
Please do not include any confidential or sensitive information in this form. This form sends information by non-encrypted e-mail which is not secure. Submitting this form does not create an attorney-client relationship.
All form fields are required.
Our central offices are conveniently located in the BB&T Corporate Center in downtown Fort Lauderdale, Florida, with easy access from I-95.
110 E Broward Blvd
Fort Lauderdale, FL 33301
Phone: (954) 462-6700
Fax: (954) 462-6567
Our Fort Lauderdale office serves greater Broward County and Miami-Dade County, including Plantation, Davie, Sunrise, Tamarac, Margate, Lauderhill, Miami Lakes, Homestead, North Miami Beach, North Bay Village, Biscayne Park, Sunny Isles Beach, Hialeah Gardens, Golden Beach, Coral Gables, Doral, Opa-Locka, Surfside, Aventura, and Key Biscayne.
Our Boca Raton office is conveniently located in the Town Center Executive Suites, with easy access from I-95.
5550 Glades Road
Boca Raton, FL 33431
Phone: (954) 462-6700
Our Boca Raton office serves northern Broward County and Palm Beach County, including Pompano Beach, Jupiter, West Palm Beach, and Palm Beach Gardens.